A warning has been issued by Tibotec, the manufacturers of Prezista (darunavir) regarding the risk of developing drug- induced hepatitis while taking the treatment. Apparently, 0.5% of clinical trial participants who took a combination including darunavir (boosted with ritonavir) developed severe hepatotoxicity. Anyone with a history of liver-related complications such as hepatitis B or C are particularly susceptible, so appropriate tests prior to starting darunavir and regular monitoring while on the drug are vital to avoid developing any hepatotoxic reaction.
Darunavir and the risk of hepatitis
From the July 2008 issue of Positive Living • By David Menadue
This article was first published in July 2008.
While the content of this article was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.
This article contains medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.
The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.
Posted online: 22 July 2008.
Last updated: 22 July 2008.
More stories about: